NO20031185D0 - Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som målspesifikt prolegemiddel - Google Patents

Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som målspesifikt prolegemiddel

Info

Publication number
NO20031185D0
NO20031185D0 NO20031185A NO20031185A NO20031185D0 NO 20031185 D0 NO20031185 D0 NO 20031185D0 NO 20031185 A NO20031185 A NO 20031185A NO 20031185 A NO20031185 A NO 20031185A NO 20031185 D0 NO20031185 D0 NO 20031185D0
Authority
NO
Norway
Prior art keywords
cytokine
selectokine
antibody
fusion protein
target specific
Prior art date
Application number
NO20031185A
Other languages
English (en)
Other versions
NO20031185L (no
Inventor
Thomas Wuerst
Dieter Moosmayer
Matthias Grell
Peter Scheurich
Original Assignee
Pfizenmaier Klaus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizenmaier Klaus filed Critical Pfizenmaier Klaus
Publication of NO20031185D0 publication Critical patent/NO20031185D0/no
Publication of NO20031185L publication Critical patent/NO20031185L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20031185A 2000-09-15 2003-03-14 Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel NO20031185L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045592A DE10045592A1 (de) 2000-09-15 2000-09-15 Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
PCT/EP2001/010730 WO2002022833A1 (de) 2000-09-15 2001-09-17 Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug

Publications (2)

Publication Number Publication Date
NO20031185D0 true NO20031185D0 (no) 2003-03-14
NO20031185L NO20031185L (no) 2003-05-05

Family

ID=7656260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031185A NO20031185L (no) 2000-09-15 2003-03-14 Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel

Country Status (22)

Country Link
US (1) US20040053829A1 (no)
EP (1) EP1317556A1 (no)
JP (1) JP2004508828A (no)
KR (1) KR20030048041A (no)
CN (1) CN1214115C (no)
AU (1) AU2001293819A1 (no)
BG (1) BG107613A (no)
BR (1) BR0113928A (no)
CA (1) CA2422759A1 (no)
DE (1) DE10045592A1 (no)
EE (1) EE200300100A (no)
HR (1) HRP20030192A2 (no)
HU (1) HUP0301693A3 (no)
IL (1) IL154185A0 (no)
MX (1) MXPA03002229A (no)
NO (1) NO20031185L (no)
PL (1) PL360540A1 (no)
RU (1) RU2003106429A (no)
SK (1) SK2812003A3 (no)
WO (1) WO2002022833A1 (no)
YU (1) YU18903A (no)
ZA (1) ZA200302008B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239403A1 (en) * 2000-12-01 2002-06-11 The Johns Hopkins University Tissue specific prodrugs
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP1736482A1 (en) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (de) * 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
EP1972350A1 (en) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Dual targeting system
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
CA2697032C (en) * 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
US20100189651A1 (en) * 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
JP5861223B2 (ja) * 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
WO2019173832A2 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
CN120463822A (zh) * 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
KR20220020879A (ko) * 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
US20220289822A1 (en) * 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US20220356221A1 (en) * 2019-09-28 2022-11-10 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
WO2021142471A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
DE19900709A1 (de) * 1999-01-11 2000-07-13 Falkenberg Frank W Eine neue Applikationsform für biologisch wirksame Substanzen zur Anwendung bei Menschen und Tieren

Also Published As

Publication number Publication date
HRP20030192A2 (en) 2005-10-31
BG107613A (bg) 2003-12-31
KR20030048041A (ko) 2003-06-18
JP2004508828A (ja) 2004-03-25
SK2812003A3 (en) 2003-11-04
EE200300100A (et) 2005-02-15
DE10045592A1 (de) 2002-03-28
WO2002022833A1 (de) 2002-03-21
CN1458977A (zh) 2003-11-26
MXPA03002229A (es) 2005-06-20
US20040053829A1 (en) 2004-03-18
AU2001293819A1 (en) 2002-03-26
HUP0301693A3 (en) 2005-11-28
EP1317556A1 (de) 2003-06-11
RU2003106429A (ru) 2004-08-27
IL154185A0 (en) 2003-07-31
HUP0301693A2 (hu) 2003-08-28
NO20031185L (no) 2003-05-05
ZA200302008B (en) 2004-06-25
BR0113928A (pt) 2003-07-22
YU18903A (sh) 2006-05-25
PL360540A1 (en) 2004-09-06
CA2422759A1 (en) 2003-03-17
CN1214115C (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
NO20031185D0 (no) Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som målspesifikt prolegemiddel
NO20032671D0 (no) Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20031188L (no) Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
DK1337527T3 (da) Indolylmaleinimidderivater som proteinkinase C-inhibitorer
DK2020408T3 (da) Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
NO20023672L (no) Sammensetninger for kontrollert frigivelse
NO20040084L (no) Peptid-baserte forbindelser
NO20030055D0 (no) Colchinolderivater som angiogenese inhibitorer
NO20031978D0 (no) Peptider som er MetAP-2 inhibitorer
NO20021239L (no) Pteridinoner som kinase-inhibitorer
DE60127920D1 (de) Zielgerät für transfemorale Osteotomie
NO20032613L (no) Farmasöytisk sammensetning som har forbedret vannlöselighet
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1442026T3 (da) Triazolderivater som cyclooxygenase (COX)-inhibitorer
DE60311035D1 (de) Schieber
PT1279877E (pt) Dispositivo para atravessamento de paredes divisorias
ITMI20020198A0 (it) (per)aloeteri
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer
DK1317448T4 (da) Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer
SE0203644D0 (sv) Vakuumsystem till tankfartyg
SE0203546D0 (sv) Vakuumsystem till tankfartyg
NO20014954D0 (no) Peptidbaserte forbindelser
DK1210333T3 (da) p-Tolylsubstituerede heterocycliske forbindelser som herbicider